SESSION I - THE EVOLVING ROLE OF CHECKPOINT INHIBITORS IN LYMPHOMAS

Chairman: P.L. Zinzani

In Hodgkin lymphoma
A.F. Herrera
In non-Hodgkin lymphoma
J. Kuruvilla
Mechanisms of resistance to checkpoint inhibitors, novel checkpoints and novel combinations
S.M. Ansell
SESSION II - BISPECIFIC T-CELL ENGAGERS IN LYMPHOMA AND MYELOMA

Chairman: C. Carlo-Stella

Clinical results of bispecific antibodies in aggressive NHL: what’s next?
M. Hutchings
Clinical results of bispecific antibodies in indolent NHL: what’s next?
L. Falchi
New bispecifics and... trispecifics
C. Thieblemont
Clinical results in multiple myeloma: BCMA, what’s next?
F. Gay
SESSION III - RESISTANCE TO BISPECIFIC T-CELL ENGAGERS

Chairman: E. Derenzini

In multiple myeloma
S.Z. Usmani
SESSION IV - DEBATE

Chairman: F. Locke

Is there a role for allogeneic transplant after bispecifics and CAR-T in NHL? No
S.J. Schuster
SESSION VI - CLINICAL UPDATES IN CAR-T THERAPIES

Chairmen: P. Corradini, M. Wang

Clinical results CAR-T for DLBCL: what’s next?
S.J. Schuster
Clinical results CAR-T for mantle cell lymphoma: what’s next?
M. Wang
Clinical results CAR-T for follicular lymphoma: what’s next?
P. Strati
Clinical results CAR-T for T-cell lymphomas: are we catching up?
S.K. Barta
Clinical results CAR-T for Hodgkin lymphoma: are we catching up?
C.A. Ramos
SESSION VIII - T-CELL BASED THERAPY TOXICITIES

Chairman: K. Rejeski

CAR-T toxicities in NHL and MM: non-relapse mortality, infections, secondary cancers and delayed neurotoxicities
K. Rejeski
Strategies to reduce early and late CAR-T toxicities
S. Kenderian
SESSION IX - CAR-T RESISTANCE AND NOVEL OPPORTUNITIES

Chairman: S.S. Neelapu

Patient selection, bridging therapy and lymphodepletion techniques
M. Jain
Microbiome, diet and host factors: how do they affect T-cell immunotherapies
M. Ruella
  • Via De’ Poeti 1/7
  • 40124 Bologna
  • segreteriasie@ercongressi.it
  • Tel. 051 6390906